| Cancer-related molecular mechanisms research | Lifetime | 24 | CN 8 | 99.79 |
| MicroRNA in disease regulation | Lifetime | 36 | CN 9 | 99.76 |
| Circular RNAs in diseases | Lifetime | 17 | CN 6 | 99.75 |
| Immune cells in cancer | Lifetime | 40 | CN 1 | 99.70 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 133 | CN 4 | 99.66 |
| Immune Cell Function and Interaction | Lifetime | 223 | CN 4 | 99.71 |
| CAR-T cell therapy research | Lifetime | 117 | CN 1 | 99.55 |
| Immunotherapy and Immune Responses | Lifetime | 231 | CN 5 | 99.61 |
| Cancer, Hypoxia, and Metabolism | Lifetime | 257 | CN 12 | 99.22 |
| COVID-19 Clinical Research Studies | Lifetime | 307 | CN 47 | 98.66 |
| RNA modifications and cancer | Lifetime | 509 | CN 51 | 98.94 |
| Long-Term Effects of COVID-19 | Lifetime | 220 | CN 14 | 97.96 |
| Cancer Cells and Metastasis | Lifetime | 248 | CN 10 | 98.81 |
| Cancer Mechanisms and Therapy | Lifetime | 129 | CN 13 | 98.52 |
| Ferroptosis and cancer prognosis | Lifetime | 218 | CN 98 | 97.27 |
| Cancer Research and Treatments | Lifetime | 363 | CN 19 | 97.92 |
| Chemokine receptors and signaling | Lifetime | 112 | CN 2 | 97.93 |
| T-cell and B-cell Immunology | Lifetime | 727 | CN 13 | 98.70 |
| RNA Interference and Gene Delivery | Lifetime | 814 | CN 156 | 98.03 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 366 | CN 15 | 97.97 |
| interferon and immune responses | Lifetime | 389 | CN 31 | 97.41 |
| Neuroinflammation and Neurodegeneration Mechanisms | Lifetime | 715 | CN 44 | 97.77 |
| Phagocytosis and Immune Regulation | Lifetime | 179 | CN 10 | 96.63 |
| Metabolism, Diabetes, and Cancer | Lifetime | 626 | CN 15 | 97.74 |
| Cancer-related gene regulation | Lifetime | 697 | CN 91 | 96.84 |
| Extracellular vesicles in disease | Lifetime | 553 | CN 173 | 95.93 |
| IL-33, ST2, and ILC Pathways | Lifetime | 297 | CN 9 | 97.07 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 295 | CN 41 | 94.46 |
| Heat shock proteins research | Lifetime | 367 | CN 6 | 96.00 |
| vaccines and immunoinformatics approaches | Lifetime | 326 | CN 9 | 96.33 |
| Cancer, Stress, Anesthesia, and Immune Response | Lifetime | 348 | CN 17 | 93.41 |
| Advanced Glycation End Products research | Lifetime | 564 | CN 53 | 93.82 |
| FOXO transcription factor regulation | Lifetime | 177 | CN 21 | 92.09 |
| Bioactive Natural Diterpenoids Research | Lifetime | 370 | CN 141 | 85.79 |
| Medicinal Plant Pharmacodynamics Research | Lifetime | 539 | CN 357 | 76.46 |
| Inflammation biomarkers and pathways | Lifetime | 590 | CN 99 | 76.20 |
| Intramuscular injections and effects | Lifetime | 597 | CN 6 | 70.44 |
| Immune Cell Function and Interaction | 2021-2025 | 2 | CN 1 | 99.77 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 3 | CN 2 | 99.64 |
| Immune cells in cancer | 2021-2025 | 4 | CN 2 | 99.87 |
| Immunotherapy and Immune Responses | 2021-2025 | 14 | CN 1 | 99.58 |
| Cancer-related molecular mechanisms research | 2021-2025 | 42 | CN 28 | 99.58 |
| Neuroinflammation and Neurodegeneration Mechanisms | 2021-2025 | 35 | CN 6 | 98.96 |
| MicroRNA in disease regulation | 2021-2025 | 52 | CN 31 | 99.16 |
| Cancer Cells and Metastasis | 2021-2025 | 31 | CN 5 | 97.94 |
| CAR-T cell therapy research | 2021-2025 | 82 | CN 2 | 99.43 |
| Cancer Research and Treatments | 2021-2025 | 22 | CN 17 | 97.92 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 160 | CN 26 | 99.37 |
| Epigenetics and DNA Methylation | 2021-2025 | 97 | CN 44 | 97.89 |
| Circular RNAs in diseases | 2021-2025 | 45 | CN 32 | 98.62 |
| RNA modifications and cancer | 2021-2025 | 155 | CN 105 | 98.42 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 80 | CN 16 | 97.24 |
| Virus-based gene therapy research | 2021-2025 | 91 | CN 19 | 96.43 |
| IL-33, ST2, and ILC Pathways | 2021-2025 | 41 | CN 3 | 96.91 |
| Ferroptosis and cancer prognosis | 2021-2025 | 217 | CN 172 | 96.40 |
| Cytokine Signaling Pathways and Interactions | 2021-2025 | 49 | CN 3 | 93.44 |
| interferon and immune responses | 2021-2025 | 117 | CN 60 | 94.00 |
| Neurological Disease Mechanisms and Treatments | 2021-2025 | 72 | CN 27 | 94.54 |
| Chemokine receptors and signaling | 2021-2025 | 30 | CN 3 | 90.41 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 584 | CN 106 | 96.35 |
| Phagocytosis and Immune Regulation | 2021-2025 | 71 | CN 27 | 91.24 |
| Cancer-related gene regulation | 2021-2025 | 171 | CN 114 | 92.01 |
| Advanced Glycation End Products research | 2021-2025 | 70 | CN 32 | 91.24 |
| Nanowire Synthesis and Applications | 2021-2025 | 213 | CN 80 | 91.07 |
| Extracellular vesicles in disease | 2021-2025 | 771 | CN 457 | 90.96 |
| T-cell and B-cell Immunology | 2021-2025 | 573 | CN 61 | 88.75 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 403 | CN 50 | 88.93 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 113 | CN 7 | 87.15 |
| Mycobacterium research and diagnosis | 2021-2025 | 508 | CN 72 | 88.16 |
| Lung Cancer Research Studies | 2021-2025 | 871 | CN 191 | 90.57 |
| Cytomegalovirus and herpesvirus research | 2021-2025 | 403 | CN 40 | 86.16 |
| Climate Change and Health Impacts | 2021-2025 | 985 | CN 271 | 87.29 |
| Eosinophilic Esophagitis | 2021-2025 | 528 | CN 19 | 89.50 |
| Cancer Mechanisms and Therapy | 2021-2025 | 394 | CN 157 | 83.30 |
| Inflammatory Biomarkers in Disease Prognosis | 2021-2025 | 486 | CN 197 | 81.12 |
| Ubiquitin and proteasome pathways | 2021-2025 | 909 | CN 393 | 81.92 |
| Heat shock proteins research | 2021-2025 | 192 | CN 30 | 78.97 |
| Lipid metabolism and disorders | 2021-2025 | 343 | CN 75 | 76.69 |
| Galectins and Cancer Biology | 2021-2025 | 446 | CN 109 | 75.80 |
| Neuroprotection in Stroke and Neurodegeneration | 2021-2025 | 439 | CN 64 | 76.33 |
| Invertebrate Immune Response Mechanisms | 2021-2025 | 478 | CN 275 | 79.31 |
| Platelet Disorders and Treatments | 2021-2025 | 997 | CN 109 | 78.07 |
| Adenosine and Purinergic Signaling | 2021-2025 | 429 | CN 90 | 74.91 |
| Intramuscular injections and effects | 2021-2025 | 81 | CN 1 | 74.24 |
| Inflammation biomarkers and pathways | 2021-2025 | 115 | CN 50 | 70.81 |
| Liver physiology and pathology | 2021-2025 | 914 | CN 397 | 66.78 |
| S100 Proteins and Annexins | 2021-2025 | 731 | CN 143 | 64.62 |
| Traditional Chinese Medicine Analysis | 2021-2025 | 893 | CN 788 | 63.02 |
| Kruppel-like factors research | 2021-2025 | 539 | CN 209 | 60.67 |
| Vascular Tumors and Angiosarcomas | 2021-2025 | 907 | CN 89 | 53.74 |
| Fibroblast Growth Factor Research | 2021-2025 | 997 | CN 295 | 54.80 |
| NF-κB Signaling Pathways | 2021-2025 | 435 | CN 172 | 52.34 |
| FOXO transcription factor regulation | 2021-2025 | 278 | CN 104 | 51.37 |
| Pomegranate: compositions and health benefits | 2021-2025 | 690 | CN 106 | 39.90 |